Featured
Generate Biomedicines Secures $400 Million in Biotech IPO
The AI-driven company will fund Phase 3 asthma trials and oncology pipelines following the year's largest biotech IPO.
The AI-driven company will fund Phase 3 asthma trials and oncology pipelines following the year's largest biotech IPO.










